Brenus Pharma is a french innovative biotech targeting high unmet needs in oncology. We developed a discovery platform for allogeneic stimulated cell-based immunotherapies such as our lead candidate STC- 1010 in mCRC.To know more, here is our website www.brenus-pharma.com.-Medical Strategy / Business Strategy / Fund raising / Biotech Launch / CMC / Regulatory / Team Management / Valorization / External Communication / Intellectual Property

Launch of Alunbrig (brigatinib), new generation targeted therapy in NSCLC ALK+Pre-launch of TAK788 in NSCLC EGFR Ins Ex 20-Medical Strategic Plan / Global ISS / KOL Managment / Innovation Launch / Immuno-Oncology

•Launch of Triplixam, the first triple combination of Servier in Hypertension.- Set up the pre awarness phase and the strategic and communication plan as a pilot-country for APAC region (+170% GR vs target in units) - Coordination with the other affiliates within South East Asia for the launch strategic plan- Organized and moderated 7 international expert board meetings.-Designed and rolled-out the phase IV study (390 patients included in 6 months). - Key accounts management and SFE responsibilities (+48% GR vs n-1 in value)- Report directly to the General Manager and manage 5 employees •Launch of Natrixam (Indapamide SR + Amlodipine besylate)-Elaborated and rolled out the local medical and marketing launch plan resulting in + 15% GR in value vs n-1 for the Hypertension franchise.-As a pilot country, support the development of the Global launch strategy with the international department-Develop and conduct training plan for the medical reps.-Managed and succeeded to win the hospital tender in the 3 key public hospitals in Singapore•Coveram, Natrilix SR Product Manager / Medical Rep (part-time field position)- Develop the mix marketing strategy to increase sales (+20% vs N-1 in units in YTD)- Key account management (50% FTE)- Organize and manage APAC regional meeting with international speaker- Work cross-functionally with sales team to develop digital patient program.

•Nephrology & Transplantation overall portfolio: Mircera, Neorecormon, Cellcept - Develop the mix marketing strategy to increase the market share (Cellcept = + 16 pts YTD)- Monitor operating costs and compliance with national budget (3,5 millions €)- Identify and present innovative and creative product solutions (Cellcept’s direct sales)- Report directly to the Marketing Director and manage 4 employees.- Work closely with the international team to build the global strategy- KOL management in international meetings (Seattle, Atlanta, Morroco,..)- Coordinate and build strong working relations with various internal organizations including sales, product development, economic affairs, juridic and IT.

•Zelboraf (Vemurafenib) Launch, 1st targeted therapy in onco-dermatology- Developed and rolled-out of global marketing launch campaign (e-detailing, multi-channel strategy)-Close collaboration with Roche Diagnostic to prepare the Medical campaign for MSL team.- Participated in exceeding sales target (ROO : + 169 %)•Erivedge (Vismodegib) Pre-launch, 1st targeted therapy against advanced basocellular carcinoma- Participated to the development of medical pre-launch campaign in relation with Roche Diagnostic

•Market analysis and evaluation: - Antidepressant market in Australia and China - Diabetology outlook & economic potential of ophthalmology drugs - Sales force effectiveness•Preparation of Valdoxan Germany, Brasil, Portugal and Australia dashboards and marketing plans•Study of the potential of 17 emerging countries, in collaboration with marketing access and medical evaluation departments and creation of a standardized reporting.•Competitive Intelligence

•Set up and Management of a suitability study of antibiotic prescriptions in two Hospitals with the partnership of a regional association (ANTIBIOLOR) in order to fight against the antibiotic resistance.•Abstract redaction and submission for the National Infectious diseases congress